June 2023

A new paradigm in the treatment of patients with diffuse large B-cell lymphoma, one of the most aggressive blood cancers

It is the first treatment in the last 30 years that represents a relative improvement of 38% in the overall survival of patients compared to standard treatment. The results of Phase III study ZUMA-7 show that this new treatment with Yescarta (axicabtagén ciloleucel, known as axicel) reduces the risk of death by 27.4%.

A new paradigm in the treatment of patients with diffuse large B-cell lymphoma, one of the most aggressive blood cancers Read More »

Scroll to Top